SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-22-068713
Filing Date
2022-03-08
Accepted
2022-03-08 07:41:16
Documents
10

Document Format Files

Seq Description Document Type Size
1 424B5 d275065d424b5.htm 424B5 846122
2 GRAPHIC g275065g05y05.jpg GRAPHIC 166624
3 GRAPHIC g275065g24a24.jpg GRAPHIC 22812
4 GRAPHIC g275065g25a25.jpg GRAPHIC 23817
5 GRAPHIC g275065g27a27.jpg GRAPHIC 23595
6 GRAPHIC g275065g28a28.jpg GRAPHIC 23689
7 GRAPHIC g275065g28s87.jpg GRAPHIC 62037
8 GRAPHIC g275065g29a29.jpg GRAPHIC 23103
9 GRAPHIC g275065g30a30.jpg GRAPHIC 26466
10 GRAPHIC g275065g96m62.jpg GRAPHIC 54010
  Complete submission text file 0001193125-22-068713.txt   1405218
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-259311 | Film No.: 22720342
SIC: 2834 Pharmaceutical Preparations